News and Views
Zimmer Biomet Hits Day Low of $85.84 Amid Price Pressure
2025-11-06 16:11:40Zimmer Biomet Holdings, Inc. has faced notable stock volatility, with significant declines over various time frames, including a year-to-date drop of 17.12%. Financial challenges are evident, including a 28.26% decrease in net profit and a high debt-equity ratio, although institutional ownership remains strong at 99.22%.
Read MoreIs Zimmer Biomet Holdings, Inc. overvalued or undervalued?
2025-11-05 11:10:20As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Agilent Technologies, Inc. has a P/E of 27.42, while GE Healthcare Technologies, Inc. stands out with a much lower P/E of 15.07, indicating that Zimmer Biomet is positioned competitively within its industry. Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -2.32% compared to the index's 16.30%. Over the past five years, the company has seen a decline of 22.03%, while the S&P 500 has gained 109.18%, further emphasizing the challenges the company faces in generating shareholder value....
Read MoreIs Zimmer Biomet Holdings, Inc. overvalued or undervalued?
2025-11-04 11:16:18As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics, with a P/E ratio of 25, a Price to Book Value of 2.25, and an EV to EBITDA of 13.72. In comparison to peers, Edwards Lifesciences Corp. has a higher P/E of 31.17, while GE Healthcare Technologies, Inc. shows a more attractive valuation with an EV to EBITDA of 12.18. Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -5.44% compared to the S&P 500's 16.30%. This underperformance over multiple periods, including a 5-year return of -24.52% versus the S&P 500's 109.18%, suggests that while the stock is fairly valued, it may face challenges in regaining investor confidence....
Read More
Zimmer Biomet Holdings, Inc. Experiences Revision in Its Stock Evaluation Metrics
2025-11-03 16:03:01Zimmer Biomet Holdings, Inc. has recently adjusted its valuation, with a current P/E ratio of 25 and a price-to-book value of 2.25. The company has experienced a decline in return metrics over various periods, contrasting with the performance of the S&P 500 and its industry peers.
Read MoreIs Zimmer Biomet Holdings, Inc. overvalued or undervalued?
2025-11-03 11:15:30As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E ratio of 31.17, while GE Healthcare Technologies, Inc. shows a more attractive EV to EBITDA of 12.18. Despite the fair valuation, Zimmer Biomet has underperformed compared to the S&P 500, with a year-to-date return of -4.80% versus the S&P 500's 16.30%. This trend continues over longer periods, indicating potential challenges ahead....
Read MoreIs Zimmer Biomet Holdings, Inc. overvalued or undervalued?
2025-11-02 11:08:49As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Edwards Lifesciences Corp. has a higher P/E ratio of 31.17, while Agilent Technologies, Inc. stands at a P/E of 27.42, indicating that Zimmer Biomet is relatively more attractively priced within its industry. Notably, the company's stock has underperformed against the S&P 500 over multiple periods, with a year-to-date return of -4.80% compared to the S&P 500's 16.30%, reinforcing the notion that it is fairly valued but may face challenges in generating positive returns in the near term....
Read More
Zimmer Biomet Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
2025-10-14 16:17:06Zimmer Biomet Holdings, Inc. has recently seen a stock price of $95.09, reflecting volatility with a yearly high of $114.72 and a low of $89.22. The company's performance has lagged behind the S&P 500, with significant declines over the past year and longer periods, indicating competitive challenges.
Read More
Zimmer Biomet Stock Forms Golden Cross, Signaling Bullish Breakout Ahead
2025-10-13 15:19:10Zimmer Biomet Holdings, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. However, the company faces challenges, with a year-over-year stock decline and mixed technical indicators suggesting volatility in investor sentiment. The Golden Cross may signal a change in market perception.
Read MoreIs Zimmer Biomet Holdings, Inc. technically bullish or bearish?
2025-10-13 11:37:26As of 10 October 2025, the technical trend for Zimmer Biomet Holdings, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing this view. The MACD is bearish on both weekly and monthly time frames, while Bollinger Bands also indicate a bearish trend. However, the daily moving averages show a mildly bullish signal. The KST presents a bullish outlook on the weekly but bearish on the monthly, and Dow Theory indicates a mildly bearish weekly trend alongside a mildly bullish monthly trend. In terms of performance, Zimmer Biomet has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -10.34% versus the S&P 500's 11.41%, and a 5-year return of -34.03% compared to the S&P 500's 88.45%....
Read More
Announcement
Corporate ActionsCorporate Actions
